Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acebutolol hydrochloride
Drug ID BADD_D00020
Description A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Indications and Usage For the management of hypertension and ventricular premature beats in adults.
Marketing Status approved; investigational
ATC Code C07AB04
DrugBank ID DB01193
KEGG ID D00597
MeSH ID D000070
PubChem ID 441307
TTD Drug ID D0HD9K
NDC Product Code 52932-0719; 65162-670; 58159-081; 65162-669; 62559-255; 51407-666; 42291-010; 62559-256; 50268-050; 53746-669; 51927-2906; 68069-0009; 53746-670; 51407-667
UNII B025Y34C54
Synonyms Acebutolol | Acetobutolol | Acebutolol Hydrochloride | M&B-17803 A | M&B 17803 A | M&B17803 A | M & B 17803A | Neptal | Prent | Rhotral | Sectral | Monitan | Apo-Acebutolol | Apo Acebutolol | ApoAcebutolol | Novo-Acebutolol | Novo Acebutolol | NovoAcebutolol
Chemical Information
Molecular Formula C18H29ClN2O4
CAS Registry Number 34381-68-5
SMILES CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye pain06.08.03.002--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Headache17.14.01.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Laryngospasm22.04.02.002--
Malaise08.01.01.003--
Mesenteric artery thrombosis24.01.08.003; 07.15.02.008--Not Available
Micturition disorder20.02.02.005--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Peyronie's disease21.12.01.002--Not Available
Pharyngitis07.05.07.004; 22.07.03.004; 11.01.13.003--
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Respiratory distress22.02.01.012--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Thrombocytopenic purpura01.08.01.003; 23.06.01.007--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Performance status decreased08.01.03.042--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages